Literature DB >> 410735

[Azlocillin--a new penicillin against Pseudomonas aeruginosa and other gram-negative bacteria].

H B König, K G Metzger, R P Mürmann, H A Offe, P Schacht, W Schröck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 410735     DOI： 10.1007/bf01639754

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  3 in total

1.  [Pharmacokinetics of azlocillin, a new semisynthetic, wide-spectrum antibiotic (author's transl)].

Authors:  K Wirth; M Schomerus; J H Hengstmann
Journal:  Infection       Date:  1976       Impact factor: 3.553

2.  [In vitro activity of mezlocillin, azlocillin and carbenicillin against bacteroidaceae with particular reference to bacteroides fragilis (author's transl)].

Authors:  H Werner; C Krassemann; J Ungerechts; H J Schmitz
Journal:  Infection       Date:  1977       Impact factor: 3.553

3.  Susceptibility of anaerobic bacteria to 23 antimicrobial agents.

Authors:  V L Sutter; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191
  3 in total
  9 in total

1.  Pharmacokinetics of Bay k 4999, a new broad-spectrum penicillin.

Authors:  R Wise; B Cadge; A P Gillett; A Bhamjee; R Livingston; P G Welling; D P Thornhill
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

2.  Comparative antibacterial activity of azlocillin, mezlocillin, carbenicillin and ticarcillin and relative stability to beta-lactamases of pseudomonas aeruginosa and klebsiella aerogenes.

Authors:  M J Basker; R A Edmondson; R Sutherland
Journal:  Infection       Date:  1979       Impact factor: 3.553

3.  Azlocillin compared with carbenicillin in the treatment of bronchopulmonary infection due to Pseudomonas aeruginosa in cystic fibrosis.

Authors:  A Penketh; M E Hodson; H Gaya; J C Batten
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

4.  [Azlocillin--a new anti-pseudomonas penicillin. A review of the literature and pharmacokinetic studies].

Authors:  Z Modr; K Dvorácek; I Janků; V Krebs
Journal:  Infection       Date:  1982       Impact factor: 3.553

5.  [Current chemotherapy of infections caused by Pseudomonas aeruginosa (author's transl)].

Authors:  A Bauernfeind; C Petermüller; M Dietzel
Journal:  Infection       Date:  1979       Impact factor: 3.553

6.  [N-formimidoyl-thienamycin: in vitro activity in bacteria with resistance to beta-lactam antibiotics or gentamicin].

Authors:  K Bartmann; R Tarbuc
Journal:  Infection       Date:  1982 Nov-Dec       Impact factor: 3.553

7.  Augmentation of the in vitro activity of azlocillin against Bacteroides fragilis by clavulanic acid.

Authors:  M B Bansal; S K Chuah; H Thadepalli
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

8.  In vitro comparison of N-formimidoyl thienamycin (MK0787) and Azlocillin with three aminoglycosides and ticarcillin against Pseudomonas aeruginosa.

Authors:  A J Matzkowitz; A L Baltch; R P Smith; N T Sutphen; M C Hammer; J V Conroy
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  Comparative bactericidal effects of azlocillin and ticarcillin against Pseudomonas aeruginosa.

Authors:  A R White; K R Comber; R Sutherland
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.